International Journal of Hematology

Papers
(The median citation count of International Journal of Hematology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-12-01 to 2024-12-01.)
ArticleCitations
Engineering the next generation of CAR-NK immunotherapies56
Recent advances in the research and management of sepsis-associated DIC55
Multiple myeloma with high-risk cytogenetics and its treatment approach44
Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine37
Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia36
Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment32
COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm24
New-onset Evans syndrome associated with systemic lupus erythematosus after BNT162b2 mRNA COVID-19 vaccination23
Prediction of clinical outcomes through assessment of sarcopenia and adipopenia using computed tomography in adult patients with acute myeloid leukemia23
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study19
Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR us19
Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma19
Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation18
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives18
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities17
Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients17
Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 202316
Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?16
Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial16
Genetic landscape of chronic myeloid leukemia15
The balance of comprehensive coagulation and fibrinolytic potential is disrupted in patients with moderate to severe COVID-1915
A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma14
Anakinra for the treatment of adult secondary HLH: a retrospective experience14
FLT3-targeted treatment for acute myeloid leukemia14
Risk factors for high-dose methotrexate-induced nephrotoxicity14
Validation of sepsis-induced coagulopathy score in critically ill patients with septic shock: post hoc analysis of a nationwide multicenter observational study in Japan13
Bringing mass spectrometry into the care of patients with multiple myeloma13
Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy13
Antibody response to COVID-19 vaccination in patients with lymphoma13
Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis12
Clinical features of 35 Down syndrome patients with transient abnormal myelopoiesis at a single institution12
Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients12
Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study12
Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation12
Updated guidelines for chronic active Epstein–Barr virus disease12
T cell clonal expansion and STAT3 mutations: a characteristic feature of acquired chronic T cell-mediated pure red cell aplasia12
The mutual crosstalk between iron and erythropoiesis11
Expression of activated integrin β7 in multiple myeloma patients11
Refined ultrasonographic criteria for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation11
Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature11
Current status and novel strategy of CML11
Patient’s age and d-dimer levels predict the prognosis in patients with TAFRO syndrome11
Effect of hypofibrinogenemia on obstetrical disseminated intravascular coagulation in Japan in 2018: a multicenter retrospective cohort study10
Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study10
Efficacy and safety of ferric citrate hydrate compared with sodium ferrous citrate in Japanese patients with iron deficiency anemia: a randomized, double-blind, phase 3 non-inferiority study10
Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin’s lymphoma: an open-label, multicenter, dose-escalation phase 1 study10
A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation10
Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study10
Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis10
The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study10
Characteristics and transplant outcome of myeloid sarcoma: a single-institute study10
Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing–Neel syndrome10
Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia10
Clostridium perfringens sepsis in three patients with acute leukemia and review of the literature10
Strong association between insufficient plasma exchange and fatal outcomes in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura10
Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility10
Prevalence and molecular spectrum of α- and β-globin gene mutations in Hainan, China10
High incidence of venous thrombosis in patients with moderate-to-severe COVID-199
Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial9
Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblasti9
Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody9
Viral, genetic, and immune factors in the oncogenesis of adult T-cell leukemia/lymphoma9
Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis9
Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial8
Recent advances in hematopoietic cell transplantation for inherited bone marrow failure syndromes8
Current and emerging therapeutic strategies in adult T-cell leukemia–lymphoma8
Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis8
Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marke8
Risk factors and prognosis of non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation8
Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis8
Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine8
Plasma proteomics associated with autoimmune coagulation factor deficiencies reveals the link between inflammation and autoantibody development8
Treatment-free remission and immunity in chronic myeloid leukemia8
Acute immune thrombocytopenia following SARS-CoV-2 vaccination in chronic ITP patients and a healthy individual8
Circulatory miR-155 correlation with platelet and neutrophil recovery after autologous hematopoietic stem cell transplantation, a multivariate analysis8
Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma8
Incidence, risk factors, and recognition of pseudohyperkalemia in patients with chronic lymphocytic leukemia8
Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges7
Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review7
Epigenetic regulation by ASXL1 in myeloid malignancies7
Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study7
The role of epigenetics in T-cell lymphoma7
Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era7
Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide7
Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China7
The role of specialized cell cycles during erythroid lineage development: insights from single-cell RNA sequencing7
Measurement of coagulation factor antibody levels is useful for diagnosis and determining therapeutic efficacy in hemorrhagic patients with autoantibodies to coagulation factor VIII and factor V: resu7
Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease7
Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia7
Utility of novel T-cell-specific extracellular vesicles in monitoring and evaluation of acute GVHD7
Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial7
The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia7
Diagnosis and treatment of disseminated intravascular coagulation in COVID-19 patients: a scoping review7
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis7
Utilization of a novel Sendai virus vector in ex vivo gene therapy for hemophilia A7
Risk prediction for delayed clearance of high-dose methotrexate in pediatric hematological malignancies by machine learning7
Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria7
Presence of bone marrow fibrosis in multiple myeloma may predict extramedullary disease7
Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation7
Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease7
Comprehensive blood coagulation potential in patients with acquired hemophilia A: retrospective analyses of plasma samples obtained from nationwide centers across Japan7
Predictive and risk factor analysis for bloodstream infection in high-risk hematological patients with febrile neutropenia: post-hoc analysis from a prospective, large-scale clinical study6
An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma6
Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3–ITD-mutated acute myeloid leukemia6
Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura6
Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study6
Relationship between serum zinc level and sepsis-induced coagulopathy6
Recent progress in ITP treatment6
Volumetric splenomegaly in patients with essential thrombocythemia and prefibrotic/early primary myelofibrosis6
Effectiveness of hyperbaric oxygen therapy for virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation6
Dual inhibition of EZH1/2 induces cell cycle arrest of B cell acute lymphoblastic leukemia cells through upregulation of CDKN1C and TP53INP16
Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies6
Quality of life and patient-reported outcomes in chronic severe neutropenia conditions6
All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 166
Cardiovascular risk factors among adult patients with haemophilia6
Early central nervous system relapse of monomorphic epitheliotropic intestinal T-cell lymphoma after cord blood transplantation6
Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal6
Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial6
Nutritional status and quality of life in adults undergoing allogeneic hematopoietic stem cell transplantation6
Selective T-cell depletion targeting CD45RA as a novel approach for HLA-mismatched hematopoietic stem cell transplantation in pediatric nonmalignant hematological diseases6
Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome6
Novel treatments for myelofibrosis: beyond JAK inhibitors6
The clinical application of SNP-based next-generation sequencing (SNP-NGS) for evaluation of chimerism and microchimerism after HLA-mismatched stem cell microtransplantation6
Phenotype-oriented anticoagulant therapy for sepsis: still a work in progress6
Resilient T-cell responses in patients with advanced cancers6
Immunological influence of serum-free manufactured umbilical cord-derived mesenchymal stromal cells for steroid-resistant acute graft-versus-host disease6
A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China6
The pathogenesis of cancer-associated thrombosis6
Severe systemic inflammation mimicking TAFRO syndrome following COVID-196
Case reports of management of aplastic anemia after COVID-19 vaccination: a single institute experience in Taiwan6
Increased serum C-reactive protein is an adverse prognostic factor in low-risk myelodysplastic syndromes5
Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy5
Outcomes in patients with acute lymphoblastic leukemia who underwent second allogeneic hematopoietic cell transplantation for relapse after first transplantation5
A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia5
Prognostic value of lymphoid marker CD7 expression in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in first morphological complete remission5
CXCR4 expression by mesenchymal stromal cells is lost after use of enzymatic dissociation agents, but preserved by use of non-enzymatic methods5
Reduced-intensity conditioning is effective for allogeneic hematopoietic stem cell transplantation in infants with MECOM-associated syndrome5
VEXAS syndrome5
Optimization of lymphapheresis for manufacturing autologous CAR-T cells5
Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pi5
Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation5
Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor5
Comprehensive molecular understanding of pediatric acute myeloid leukemia5
Induction of enucleation in primary and immortalized erythroid cells5
Progress of modern imaging modalities in multiple myeloma5
Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma5
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial5
Latest trends in the incidence of Helicobacter pylori-uninfected gastric mucosa-associated lymphoid tissue lymphoma at the Cancer Institute Hospital, Japan5
Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological maligna5
Reference intervals of red blood cell parameters and platelet count for healthy adults in Japan5
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience5
ORIHIME study: real-world treatment patterns and clinical outcomes of 338 patients with acquired hemophilia A from a Japanese administrative database5
Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan5
Biopsy remains indispensable for evaluating bone marrow involvement in DLBCL patients despite the use of positron emission tomography5
New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism5
Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis5
Spontaneous regression of dasatinib-related primary effusion lymphoma-like lymphoma5
Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study5
Salvage therapy with 2-chlorodeoxyadenosine for refractory and relapsed pediatric Langerhans cell histiocytosis: an updated nationwide survey in Japan5
Asciminib as a third line option in chronic myeloid leukemia5
ETV6-related thrombocytopenia associated with a transient decrease in von Willebrand factor5
The acidic domain of Hmga2 and the domain’s linker region are critical for driving self-renewal of hematopoietic stem cell4
Bosutinib-induced lung injury: a report of two cases and literature review4
Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine–bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma4
Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation4
Histidine decarboxylase deficiency inhibits NBP-induced extramedullary hematopoiesis by modifying bone marrow and spleen microenvironments4
Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial4
Fixed- versus variable-dose prothrombin complex concentrate protocol for vitamin K antagonist reversal4
Improving allogeneic stem cell transplantation in myelofibrosis4
Heme as a differentiation-regulatory transcriptional cofactor4
Practical management of patients with hematological diseases during the COVID-19 pandemic in Japan4
Dasatinib induces endothelial-to-mesenchymal transition in human vascular-endothelial cells: counteracted by cotreatment with bosutinib4
Increasing numbers of CD19 + CD24highCD38high regulatory B cells and pre-germinal center B cells reflect activated autoimmunity and predict future treatment response in patients with untreated immune 4
A meta-analysis of risk factors associated with platelet transfusion refractoriness4
Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma4
Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency4
Autoimmune-mediated thrombocytopenia after allogeneic hematopoietic stem cell transplantation: significance of detecting reticulated platelets and glycoprotein-specific platelet autoantibodies4
Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia4
Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient4
JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia4
Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T4
Novel technologies for improving the safety and efficacy of CAR-T cell therapy4
Evolution and optimization of therapies for acute lymphoblastic leukemia in infants4
Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphom4
Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute4
RNA modifications in hematological malignancies4
Unresolved issues in allogeneic hematopoietic cell transplantation for non-malignant diseases4
The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy4
Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis4
Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children’s Cancer Group4
Clinical, laboratory, and mutational profile of children with glucose phosphate isomerase deficiency: a single centre report4
Characteristics and predictors of post-transplant-associated hemophagocytic lymphohistiocytosis in adults4
Risk factors for unplanned removal of central venous catheters in hospitalized children with hematological and oncological disorders4
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation4
Association between the pharmacokinetics of rabbit anti-thymocyte globulin and acute graft-versus-host disease in patients who received haploidentical hematopoietic stem cell transplantation4
Prevention of acute graft-versus-host disease in adult T-cell leukemia–lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation4
A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation4
Romidepsin-induced durable remission for relapsed nodal peripheral T-cell lymphoma with T follicular helper phenotype after allogeneic hematopoietic cell transplantation4
Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome4
MPL exon 10 mutations other than canonical MPL W515L/K mutations identified by in-house MPL exon 10 direct sequencing in essential thrombocythemia4
Novel immunotherapies in multiple myeloma4
Extracellular vesicle-mediated immunoregulation in cancer4
Fetal hemoglobin level predicts lower-risk myelodysplastic syndrome4
FLT3 targeting in the modern era: from clonal selection to combination therapies4
Isolated thrombosis after COVID-19 vaccination: case series4
A novel germline GATA2 frameshift mutation with a premature stop codon in a family with congenital sensory hearing loss and myelodysplastic syndrome4
Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance4
Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma with HTLV-1-associated myelopathy4
Familial hemophagocytic lymphohistiocytosis syndrome due to lysinuric protein intolerance: a patient with a novel compound heterozygous pathogenic variant in SLC7A74
Acquired hypofibrinogenemia in a patient with multiple myeloma4
Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice3
Treatment options and pregnancy management for patients with PV and ET3
Decision analysis of allogeneic bone marrow transplantation versus immunosuppressive therapy for young adult patients with aplastic anemia3
NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia3
Rapid blood cell recovery with immunosuppressive therapy combined with romiplostim in a patient with very severe hepatitis-associated aplastic anemia who underwent liver transplantation3
Circulating CD34+ cells of primary myelofibrosis patients contribute to myeloid-dominant hematopoiesis and bone marrow fibrosis in immunodeficient mice3
Allogeneic hematopoietic stem cell transplantation for inherited metabolic disorders3
Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation3
Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia3
Ribosome profiling analysis reveals the roles of DDX41 in translational regulation3
Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial3
Evaluation of beta-2 microglobulin, erythropoietin and tobacco use in polycythemic cases3
Pathological and molecular analysis of a composite lymphoma of mantle cell lymphoma and Epstein–Barr virus-positive follicular lymphoma3
Screening for M-proteinemia consisting of monoclonal gammopathy of undetermined significance and multiple myeloma for 30 years among atomic bomb survivors in Hiroshima3
A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)3
New onset of hypomegakaryocytic thrombocytopenia with the potential for progression to aplastic anemia after BNT162b2 mRNA COVID-19 vaccination3
Prediction of major bleeding events in 1381 patients with essential thrombocythemia3
NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan3
Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients3
Daily combined measurement of platelet count and presepsin concentration can predict in-hospital death of patients with severe coronavirus disease 2019 (COVID-19)3
Very early death within 30 days after diagnosis in patients with acute myeloid leukemia3
Newly diagnosed extranodal NK/T-cell lymphoma, nasal type, at the injected left arm after BNT162b2 mRNA COVID-19 vaccination3
Eltrombopag restores erythropoiesis in refractory adult acquired pure red cell aplasia3
Chronic liver graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients during tapering or after stopping calcineurin inhibitors3
Mycobacterial lymphadenitis without granuloma formation in a patient with anti-interferon-gamma antibodies3
Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR13
Clinical significance of human endogenous retrovirus K (HERV-K) in multiple myeloma progression3
Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study3
Clinical and microbiological characteristics of bacterial meningitis in umbilical cord blood transplantation recipients3
EBV-PTLD in a patient after haploidentical stem-cell transplantation with post-transplant cyclophosphamide3
Real-world outcomes of AIDS-related Burkitt lymphoma: a retrospective study of 78 cases over a 10-year period3
Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets3
Peripartum management of hereditary thrombophilia: results of primary surveillance in Japan3
Cryopreserved versus fresh peripheral blood allogeneic stem cell transplantation outcomes in patients receiving post-transplant cyclophosphamide for graft-versus-host prophylaxis during the COVID-19 p3
Newly diagnosed follicular lymphoma during pembrolizumab treatment for lung cancer3
Companion gene mutations and their clinical significance in AML with double or single mutant CEBPA3
Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma3
Glycosylated ferritin as an improved marker for post-transfusion iron overload3
Characterization of localized macrophages in bronchiolitis obliterans after allogeneic hematopoietic cell transplantation3
Lymphoma during pregnancy in Japan: a multicenter retrospective cohort study3
0.13144588470459